Sucampo is a member of the Association of the British Pharmaceutical Industry, a leading organization that represents innovative, research-based biopharmaceutical companies and ensures ethics across the industry.
Biotechnology Industry Organization (BIO)
Sucampo is an active member of BIO, the world’s largest biotechnology trade organization across the United States and in more than 30 other nations. BIO’s mission is to be the champion of biotechnology and an advocate for member organizations—both large and small.
Please click here to view BIO’s Time Is Precious video.
As an active member of CDISC, we support the vision to inform patient care and safety through higher quality medical research.
Sucampo is a member of PhRMA, whose mission to encourage the discovery of important new medicines for patients by pharmaceutical and biotechnology research companies is well aligned with our own.
Tech Council of Maryland (TCM)
We are pleased to help support collaboration among the local biotechnology community through our membership in the Tech Council of Maryland.
Vereinigung Pharmafirmen in der Schweiz (Association of Pharmaceutical Companies in Switzerland) (VIPS)
With operations in Switzerland, Sucampo is an active member of pharmaceutical industry association Vereinigung Pharmafirmen in der Schweiz.
We are pleased to support the S&R Foundation, whose mission is to support talented individuals with great potential and high aspirations in the arts, sciences, and social entrepreneurship, especially those who are furthering international cultural collaboration. Through the S&R Foundation sponsorship, we support the Halcyon Incubator, which is designed to transform ideas into scalable ventures to achieve meaningful social outcomes.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.